By linear regression analysis adjusted for age and diabetes duration at GLP-1 RA initiation, diabetes chronic complications, and cardiovascular diseases, we explored whether HbA1c change during therapy was influenced by HbA1c level at baseline. The gene discussed is GCG; the disease is cardiovascular disorder.